The panel recommended broadening options for starting ART at a CD4 count above 350 cells/mm3 and to include people with active hepatitis B or C infection, cardiovascular disease risk, or compromised kidney function [1] The panel set no upper CD4 limit on when treatment should begin. Here, CD4 is linked to hepatitis B virus infection.